These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 30466512)

  • 21. Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial.
    Chouairi F; Pacor J; Miller PE; Fuery MA; Caraballo C; Sen S; Leifer ES; Felker GM; Fiuzat M; O'Connor CM; Januzzi JL; Friedman DJ; Desai NR; Ahmad T; Freeman JV
    Mayo Clin Proc Innov Qual Outcomes; 2021 Apr; 5(2):447-455. PubMed ID: 33997640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
    Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
    Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study.
    Pahuja M; Leifer ES; Clarke JD; Ahmad T; Daubert MA; Mark DB; Cooper L; Desvigne-Nickens P; Fiuzat M; Adams K; Ezekowitz J; Whellan DJ; Januzzi JL; O'Connor CM; Felker GM; Piña IL
    Prog Cardiovasc Dis; 2022; 71():79-85. PubMed ID: 35490873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study.
    Gaggin HK; Mohammed AA; Bhardwaj A; Rehman SU; Gregory SA; Weiner RB; Baggish AL; Moore SA; Semigran MJ; Januzzi JL
    J Card Fail; 2012 Aug; 18(8):626-34. PubMed ID: 22858078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHF.
    Sanders-van Wijk S; Muzzarelli S; Neuhaus M; Kiencke S; Maeder M; Estlinbaum W; Tobler D; Mayer K; Erne P; Pfisterer ME; Brunner-La Rocca HP;
    Eur J Heart Fail; 2013 Aug; 15(8):910-8. PubMed ID: 23666681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.
    Gheorghiade M; Greene SJ; Butler J; Filippatos G; Lam CS; Maggioni AP; Ponikowski P; Shah SJ; Solomon SD; Kraigher-Krainer E; Samano ET; Müller K; Roessig L; Pieske B;
    JAMA; 2015 Dec; 314(21):2251-62. PubMed ID: 26547357
    [TBL] [Abstract][Full Text] [Related]  

  • 27. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.
    Kristensen SL; Mogensen UM; Jhund PS; Rørth R; Anand IS; Carson PE; Desai AS; Pitt B; Pfeffer MA; Solomon SD; Zile MR; Køber L; McMurray JJV
    Circ Heart Fail; 2019 Mar; 12(3):e005766. PubMed ID: 30871349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
    Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
    Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomarker responses during and after treatment with nesiritide infusion in patients with decompensated chronic heart failure.
    Miller WL; Hartman KA; Burritt MF; Borgeson DD; Burnett JC; Jaffe AS
    Clin Chem; 2005 Mar; 51(3):569-77. PubMed ID: 15615816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Importance of Worsening Heart Failure in Ambulatory Patients: Definition, Characteristics, and Effects of Amino-Terminal Pro-B-Type Natriuretic Peptide Guided Therapy.
    Mallick A; Gandhi PU; Gaggin HK; Ibrahim N; Januzzi JL
    JACC Heart Fail; 2016 Sep; 4(9):749-55. PubMed ID: 27179830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial.
    Čelutkienė J; Čerlinskaitė-Bajorė K; Cotter G; Edwards C; Adamo M; Arrigo M; Barros M; Biegus J; Chioncel O; Cohen-Solal A; Damasceno A; Diaz R; Filippatos G; Gayat E; Kimmoun A; Léopold V; Metra M; Novosadova M; Pagnesi M; Pang PS; Ponikowski P; Saidu H; Sliwa K; Takagi K; Ter Maaten JM; Tomasoni D; Lam CSP; Voors AA; Mebazaa A; Davison B
    Circ Heart Fail; 2024 Apr; 17(4):e011221. PubMed ID: 38445950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials.
    Brunner-La Rocca HP; Eurlings L; Richards AM; Januzzi JL; Pfisterer ME; Dahlström U; Pinto YM; Karlström P; Erntell H; Berger R; Persson H; O'Connor CM; Moertl D; Gaggin HK; Frampton CM; Nicholls MG; Troughton RW
    Eur J Heart Fail; 2015 Dec; 17(12):1252-61. PubMed ID: 26419999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health Status Predicts Short- and Long-Term Risk of Composite Clinical Outcomes in Acute Heart Failure.
    Hu D; Liu J; Zhang L; Bai X; Tian A; Huang X; Zhou K; Gao M; Ji R; Miao F; Li J; Li W; Ge J; He G; Li J
    JACC Heart Fail; 2021 Dec; 9(12):861-873. PubMed ID: 34509406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE; Lombraña A; Duarte P; Di Gennaro F
    J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial.
    Greene SJ; Maggioni AP; Fonarow GC; Solomon SD; Böhm M; Kandra A; Prescott MF; Reimund B; Hua TA; Lesogor A; Zannad F; Gheorghiade M;
    Eur J Heart Fail; 2015 Jan; 17(1):98-108. PubMed ID: 25597870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. N-terminal pro-B-type natriuretic peptide-guided therapy in patients hospitalized for acute heart failure.
    Carubelli V; Lombardi C; Lazzarini V; Bonadei I; Castrini AI; Gorga E; Richards AM; Metra M
    J Cardiovasc Med (Hagerstown); 2016 Nov; 17(11):828-39. PubMed ID: 27322401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study.
    Jhund PS; Anand IS; Komajda M; Claggett BL; McKelvie RS; Zile MR; Carson PE; McMurray JJ
    Eur J Heart Fail; 2015 Aug; 17(8):809-17. PubMed ID: 25921853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization and prediction of adverse events from intensive chronic heart failure management and effect on quality of life: results from the pro-B-type natriuretic peptide outpatient-tailored chronic heart failure therapy (PROTECT) study.
    Gandhi PU; Szymonifka J; Motiwala SR; Belcher AM; Januzzi JL; Gaggin HK
    J Card Fail; 2015 Jan; 21(1):9-15. PubMed ID: 25463415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction.
    Zile MR; Lindenfeld J; Weaver FA; Zannad F; Galle E; Rogers T; Abraham WT
    J Am Coll Cardiol; 2020 Jul; 76(1):1-13. PubMed ID: 32616150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.